4997 |
A Journey of PCSK9 Inhibitors: From Genetics To Clinics |
David Joel Cohen |
Apr. 27. 19 |
4996 |
The Benefit of Ezetimibe/Atorvastatin Combination in Coronary Patients Treatment |
Soo-Joong Kim |
Apr. 27. 19 |
4995 |
TAVR Low Risk Trials: Can It Be Standard? |
Alain G. Cribier |
Apr. 27. 19 |
4994 |
Evidence-based Optimal Bypass Surgery |
David Paul Taggart |
Apr. 27. 19 |
4993 |
Optimal Antithrombotics for Complex Patients: Different Drugs, Dosing, or Duration? |
Davide Capodanno |
Apr. 27. 19 |
4992 |
Anticoagulation for TAVR: GALILEO, and Yet It Moves. |
Duk-Woo Park |
Apr. 27. 19 |
4991 |
Deep Dive into Mitraclip Trials for Functional MR |
Gregg W. Stone |
Apr. 27. 19 |
4990 |
Case 1: Unexpanded ISR - Challenging and Optimal Treatment |
Jung-Min Ahn |
Apr. 27. 19 |
4989 |
Mechanical Properties of the Magmaris Bioresorbable Scaffold |
John Ormiston |
Apr. 27. 19 |
4988 |
Practical Considerations for Long DAPT Based on Lesion and Patient Selections |
Tullio Palmerini |
Apr. 27. 19 |